Zhejiang East Asia Pharmaceutical Balance Sheet Health
Financial Health criteria checks 4/6
Zhejiang East Asia Pharmaceutical has a total shareholder equity of CN¥2.0B and total debt of CN¥776.9M, which brings its debt-to-equity ratio to 38.6%. Its total assets and total liabilities are CN¥3.4B and CN¥1.4B respectively. Zhejiang East Asia Pharmaceutical's EBIT is CN¥110.9M making its interest coverage ratio -8.6. It has cash and short-term investments of CN¥698.4M.
Key information
38.6%
Debt to equity ratio
CN¥776.92m
Debt
Interest coverage ratio | -8.6x |
Cash | CN¥698.44m |
Equity | CN¥2.02b |
Total liabilities | CN¥1.38b |
Total assets | CN¥3.39b |
Recent financial health updates
No updates
Recent updates
Zhejiang East Asia Pharmaceutical's (SHSE:605177) Solid Profits Have Weak Fundamentals
May 06Zhejiang East Asia Pharmaceutical Co., Ltd. (SHSE:605177) Stock Catapults 26% Though Its Price And Business Still Lag The Market
Apr 23Take Care Before Diving Into The Deep End On Zhejiang East Asia Pharmaceutical Co., Ltd. (SHSE:605177)
Feb 28Financial Position Analysis
Short Term Liabilities: 605177's short term assets (CN¥1.6B) exceed its short term liabilities (CN¥648.7M).
Long Term Liabilities: 605177's short term assets (CN¥1.6B) exceed its long term liabilities (CN¥727.6M).
Debt to Equity History and Analysis
Debt Level: 605177's net debt to equity ratio (3.9%) is considered satisfactory.
Reducing Debt: 605177's debt to equity ratio has increased from 10.2% to 38.6% over the past 5 years.
Debt Coverage: 605177's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: 605177 earns more interest than it pays, so coverage of interest payments is not a concern.